Tremelimumab (Imjudo®) in combination with durvalumab for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC)

Rothschedl, E. and Wolf, S. (2023): Tremelimumab (Imjudo®) in combination with durvalumab for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). Oncology Fact Sheet Nr. 118.

[thumbnail of Oncology Fact Sheet Nr.118.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
843kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WI Digestive system > WI 700-770 Liver. Billary tract
Language:	English
Series Name:	Oncology Fact Sheet Nr. 118
Deposited on:	01 Feb 2023 15:39
Last Modified:	01 Feb 2023 15:50

Repository Staff Only: item control page